目的：观察在宫颈癌患者同步放化疗后应用拓扑替康联合顺铂与紫杉醇联合顺铂两种化疗方案巩固治疗的疗效及毒副反应。方法：回顾性分析58例根治性放化疗及术后存在淋巴结转移同步放化疗后的宫颈癌患者的临床资料，其中应用拓扑替康联合顺铂巩固化疗18例（A组），应用紫杉醇联合顺铂巩固化疗22例（B组），未进行巩固化疗者18例（C组），治疗后随访3年（36个月），比较3组的疗效及毒副反应。结果：3组复发率差异无统计学意义（P>0.05），3组3年平均疾病无进展生存期（PFS）及总生存期（OS）比较差异无统计学意义（P>0.05）。最常见的毒副反应为中性粒细胞减少症，A组脱发及周围神经系统反应的发生率较B组低（P<0.05）。结论：根治性放化疗及术后存在淋巴结转移的宫颈癌患者同步放化疗后应用拓扑替康联合顺铂及紫杉醇联合顺铂巩固治疗，与放疗后无巩固化疗患者相比，3年PFS及OS无明显差异，拓扑替康联合顺铂化疗副反应轻。

[1] 叶春萍,余宁珠.Ⅰb2-Ⅱb期宫颈癌患者数钱新辅助化疗的疗效观察[J].现代医学,2012,40(5):562-565.
[2] 樊庆春,李佩玲,王红丽.宫颈癌188例临床特点分析[J].现代医学,2013,41(5):341-343.
[3] HARRY J L,BRIAN N B,EDWARD C G,et al.Randomized Phase Ⅲ Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix:A Gynecologic Oncology Group Study[J].Int J Clin Oncol,2005,23(21):4626-4633.
[4] SAKURAGI N.Up-to-date management of lymph node metastasis and the role of tailred lymphadenenctomy in cervical cancer[J].Int J Clin Oncol,2007,12:165-175.
[5] BERMAN M L,KEYS H,CREASMAN W.Survival and patterns of recurrence incervical cancer metastatic to periaortic lymph nodes[J].Gynecol Oncol,1984,19:8-16.
[6] BENEDETTI P P,BASILE S,ANGIOLI R.Pelvic and aortic lymphadenectomyin cervical cancer:the standardization of surgicalprocedure and its clinical impact[J].Gynecol Oncol,2009,113:284-290.
[7] VIDAURRETA J,BERMUDEZ A,di PAOLA G,et al.Laparoscopicstaging in locally advanced cervical carcinoma:a new possiblephilosophy? [J].Gynecol Oncol,1999,75:366-371.
[8] KIM Y B,CHO J H,KEUM K C,et al.Concurrent chemoradiotherapy followed by adjuvantchemotherapy in uterine cervical cancer patients with high-riskfactors[J].Gynecol Oncol,2007,104:58-63.
[9] AKIKO A,HIROYUKI F,MASATO N,et al.Adjuvant chemotherapy following concurrent chemoradiotherapy for uterine cervical cancer with lymphadenopathy[J].Onocl Letters,2012,3:571-576.
[10] CHOI C H,LEE J W,KIM W Y,et al.Phase Ⅱ study of consolidation chemotherapyafter concurrent chemoradiation in cervical cancer:preliminaryresults[J].Int J Rad Oncol Biol Phys,2007,68:817-822.
[11] ROSE P G,LESSING J A,GERSHENSON D M,et al.Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix:a gynecologiconcology group study[J].J Clin Oncol,1999,17:2676-2680.